MTRC is pleased to introduce a new service to help bridge the gap between clinical research and the evidence expectations of European HTA and reimbursement bodies.

In May 2025, the Ministry of Health, Welfare, and Sport provided further details on terminating "Subsidy Scheme for Promising Care". The program will be discontinued as of January 1, 2026, without any follow-up measures or financing. No new rounds for submission of proposals will be available. Nothing will change for the 28 ongoing projects and projects expected to be awarded later in 2025 as a result of the last completed rounds.

On May 6, 2025, NHS England issued an updated version of the National Genomic Test Directory for 2025/26, which lists genomic tests commissioned by NHS England via Genomic Laboratory Hubs. One new code (test-indication combination) was introduced in the Test Directory for cancer, and one for rare and inherited diseases.

On April 22, 2025, the Innovation Committee at the Federal Joint Committee (G-BA) announced the receipt of 156 applications (project ideas) for innovation funding of projects for new forms of care. The majority of applications (n=117) were submitted in response to topic-specific funding calls, including integration of AI systems into healthcare structures and processes, strengthening child and youth health, and women's health. A decision on which project ideas will be invited to submit full proposals is expected in the fourth quarter of 2025.

On April 30, 2025, the Federal Council approved the new outpatient reimbursement system, comprising the TARDOC catalog of individual service tariffs (ambulatory settings) and the flat-rate system (day case settings). The approval is valid until December 31, 2028, allowing for potential adjustments post-implementation. The TARDOC and outpatient flat rates will take effect on January 1, 2026.

MTRC is pleased to announce the release of its latest White Paper: "Best Reporting Checklists for Studies of Medical Devices". This White Paper explores the best reporting checklists for medical device studies (CONSORT, STROBE, STARD, PRISMA, PRISMA-DTA, SPIRIT, and TIDieR), their key components, and how they improve research transparency.

MTRC is pleased to announce the release of its latest White Paper: "General Market Access Landscape for Health Apps in Europe". This document provides a structured overview of the reimbursement landscape for health apps in three major European countries: England, France, and Germany.

In March-April 2025, Health Technology Wales (HTW) accomplished one full appraisal of permanent implant brachytherapy devices for unresectable pancreatic cancer. Five Med Tech-related Topic Exploration Reports were published (on superior rectal artery embolization, glucose monitoring systems in neonates, gender-affirming surgery, telemetric intracranial pressure monitoring, tumor-profiling tests to guide bisphosphonate treatment in cancer).

Meet MTRC’s Senior Reimbursement Consultant, Julia Mazur, at the Pharma 4.0 - Digital Healthcare Conference in Berlin. Visit us at Booth #9 to explore tailored solutions in market access, health economics, and evidence synthesis for complex MedTech challenges. Don’t miss Dr. Borisenko’s expert talk on the reimbursement of digital technologies in Europe on 22 May at 10:50 AM.

MTRC is pleased to announce the release of its latest White Paper: "Case study: Market Access Pathway for Preeclampsia Predictive Tests in Germany and Norway". This document provides a detailed case study on how developers of IVD tests can effectively navigate reimbursement pathways in key European markets using the examples of pathways in Germany and Norway.

On May 01, 2025, the Dutch Healthcare Authority (NZa) published the first release of the 2026 DRG package (RZ26a). Three new procedure codes, seven new supplementary payments (OZPs), one new diagnosis code, and two new DRGs will be implemented across in-vitro diagnostics, obstetrics and gynecology, neurology and neurosurgery, cardiovascular and other technology groups.

In April 2025, the HTA body of Tuscany Regional Healthcare published six rapid HTA reports (five new assessments and one reassessment) of medical devices in the cardiovascular, peripheral vascular, endoscopy, and dermatology fields.